References
- Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.
- Planchard D, Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. [cited 2020 Sep 22]. Available from: https://www.esmo.org/content/download/227453/3874538/1
- Arrieta O, Cardona AF, Lara-Mejía L, et al. Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. Crit Rev Oncol Hematol. 2020;153:103033.
- Clark J. COVID-19 precipitates sharp decline in cancer testing, diagnoses. [cited 2020 Sep 22]. Available from: https://www.clinicalomics.com/topics/molecular-dx-topic/molecular-diagnostics-in-vitro-diagnostics/covid-19-precipitates-sharp-decline-in-cancer-testing-diagnoses/
- Malapelle U, Pisapia P, Iaccarino A, et al. Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. J Clin Pathol. 2020;31. DOI:10.1136/jclinpath-2020-206957.
- Zhang H, Xie C, Hunag Y. Treatment and outcome of a patient with lung cancer infected with severe acute respiratory syndrome coronavirus-2. J Thorac Oncol. 2020;15(5):e63–e64.
- Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50.
- Davis AP, Boyer M, Lee JH, et al. COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy. 2020;12(8):545–548.
- Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nature Med. 2020;26(8):1218–1223.
- Ottaviano M, Curvietto M, Rescigno P, et al. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. J Immunother Cancer. 2020;8(2):e001154.
- Sha Z, Chang K, Mi J, et al. The impact of the COVID-19 pandemic on lung cancer patients. Ann Palliat Med. 2020;9(5):3373–3378.
- ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer. [cited 2020 Sep 22]. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era
- Conway L Lung cancer and mesothelioma service guidance during the COVID-19 pandemic. United Kingdom Lung Cancer Coalition. [cited 2020 Sep 22]. Available from: https://www.uklcc.org.uk/lung-cancer-and-mesothelioma-service-guidance-during-the-covid-19-pandemic/
- Trama A, Proto C, Whisenant JG, et al. Supporting clinical decision-making during the SARS-CoV-2 pandemic through a global research commitment: the TERAVOLT experience. Cancer Cell. 2020 9;38(5):602–604.